Navigation Links
Results from a study testing methylphenidate for cancer-related fatigue
Date:6/2/2010

CHICAGO -- Cancer-related fatigue is often a major problem for cancer patients, beginning at diagnosis, during treatment and after completing therapy. Researchers at Mayo Clinic (http://www.mayoclinic.org/oncology-rst/) and the North Central Cancer Treatment Group (http://ncctg.mayo.edu/) (NCCTG) recently completed a study testing methylphenidate in the treatment of cancer-related fatigue and found that, while it did not improve fatigue for a broad group of patients, the data did not rule out a benefit for those with stage III/IV cancer. Results of this NCCTG study, N05C7, will be presented on Sunday, June 6, 2010, at the American Society of Clinical Oncology (http://www.asco.org/) annual meeting in Chicago.

VIDEO ALERT: Additional audio and video resources, including excerpts from an interview with Dr. Deb Barton is available on the Mayo Clinic News Blog (http://newsblog.mayoclinic.org/2010/06/02/mayo-clinic-study-shows-drug-may-be-effective-in-treating-cancer-related-fatigue-in-some-patients/).

"Cancer-related fatigue can impact a patient's ability to tolerate therapy and their overall quality of life," says Debra Barton, R.N., Ph.D., associate professor of oncology at Mayo Clinic in Rochester, Minn., and an investigator for the study. "While our study did not demonstrate improvement in fatigue for a broad patient population, our results do not rule out some benefit for patients with advanced cancer and point to the need for further research."

The study included 148 adult patients with cancer-related fatigue. Of these, 74 were randomized to receive long-acting methylphenidate and 74 were randomized to receive a placebo over a four-week period. Patients taking methylphenidate were titrated from 1 to 3 tablets in order to reach the target dose of 54 mg per day. To be part of the study, patients had to report fatigue that was defined as a score of greater than or equal to 4 on an 11-point Brief Fatigue Inventory (BFI) scale.

Methylphenidate is one of a group of psychostimulants that "wake up" or stimulate the central nervous system in the brain, producing chemicals such as dopamine and norepinephrine, which cause a person to be alert. In this study, a long-acting dose was selected to deliver a constant level of medication in the bloodstream throughout the day.

In the study, all participants rated their usual fatigue on the BFI every week for four weeks. Fatigue was rated on a scale of 0 to 10, with 0 being no fatigue and 10 being severe fatigue.

Results indicated no significant difference between the methylphenidate and placebo groups for usual fatigue over the four-week period. "In patients with stage III/IV disease, however, there appeared to be a difference in the fatigue score between the two arms," says Dr. Barton. "In addition, there was a trend for patients receiving methylphenidate to be more satisfied with their treatment compared to those on the placebo arm. Caution should be used in interpreting these results, as this was an exploratory analysis and should only be used to generate hypotheses for future research," Dr. Barton says.

As far as side effects, Dr. Barton adds, "Anxiety and appetite loss were more prominent in patients on the treatment arm. There was no significant difference in the incidence of other potential side effects such as insomnia and dizziness between the two groups, but side effects, in general, were more often observed in the patients receiving the active drug."

"When considering using methylphenidate in the treatment of cancer-related fatigue, patients and their physicians need to consider the benefits and side effects of the medication," says Dr. Barton.

According to Dr. Barton, "Currently, we are developing a new study to test a newer psychostimulant medication for cancer-related fatigue in patients with advanced cancer. Hopefully, it will be more effective and less toxic."


'/>"/>

Contact: Karl Oestreich
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Tracking PSA Test Results Over Time Gives Clues to Cancer
2. Local SEO Tampa Firm Bayshore Solutions Bring Revenue Results to Premier Online Shoe Store Peltz Shoes
3. Genentech uses Complete Genomics human genome sequencing service to compare tumor and normal genome in patient with non-small cell lung cancer; results published in Nature
4. New treatment approach to rare cancer results in prolonged survival
5. Simple change results in fewer unnecessary imaging exams for patients
6. Book Delivers Latest ADHD Research, Treatments & Results
7. Results of physician cost profiling can vary widely, study finds
8. First Communications, Inc. Announces Audited Results for the Year Ended December 31, 2009
9. With Cosmetic Surgery Becoming More Common, Ft. Lauderdale Doctor says Choosing a Board Certified Plastic Surgeon is Important for Safe, Natural-Looking Results
10. Sponsoring by the pharmaceutical industry can bias the results of drug studies
11. Phase II study of an oral therapy for Gaucher disease yields positive results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... PISCATAWAY, N.J. (PRWEB) , ... February 08, 2016 ... ... of protective footwear and clothing, announced expansion into Canada to provide its range ... has opened a sales office in Quebec City that will provide bilingual customer ...
(Date:2/8/2016)... GA (PRWEB) , ... February ... ... technology and security executive networking and relationship-marketing firm, announced today that nominations ... 2016 Information Security Executive® (ISE®) West Awards. , Awards include the ...
(Date:2/8/2016)... ... 2016 , ... GrassrootsHealth published data from its D*action public ... in the GrassrootsHealth cohort with substantially higher vitamin D levels than a cohort ... states Carole Baggerly, Director of GrassrootsHealth, “the safety and benefits of vitamin ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... The ... annually in this country. The AutismOne 2016 Conference, which is being held May 25-29 ... often won’t hear elsewhere about helpful interventions and causes of chronic illness in children. ...
(Date:2/7/2016)... ... February 07, 2016 , ... Dr. Todd ... to his medical and surgical expertise. Technically known as deoxycholic acid or previously ... as a non-surgical alternative for reduction of fat below the chin (aka the ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... -- http://www.researchandmarkets.com/research/x6mkjm/knee ) has announced the ... by Product Type (Primary (Cemented & Cementless), Partial, ... Japan, Bric, Turkey, Indonesia - Global Analysis and ... --> http://www.researchandmarkets.com/research/x6mkjm/knee ) has announced ... Market by Product Type (Primary (Cemented & Cementless), ...
(Date:2/8/2016)...  Avista Pharma Solutions ("Avista Pharma") announced today that ... Officer (CFO). Mr. Setzer is a finance and operations ... roles within growing technology and life science companies. Prior ... Director of Finance at INC Research, a publicly traded ... . Previously, Mr. Setzer served as CFO of Expression ...
(Date:2/8/2016)... Therapeutics, Inc. announced today that the United States Patent and ... the use of NephroFlow to treat acute kidney injury (AKI). ... "We are pleased to secure our rights to such a ... HemaFlo,s founder, said, "We are pleased to secure our rights ... Dale Peterson , PhD, HemaFlo,s founder, said, "We are pleased ...
Breaking Medicine Technology: